Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04233567 · ClinicalTrials.gov registry record · Phase 2
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
A Phase 2 study, sponsored by Sameek Roychowdhury.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT04233567 is a Phase 2 study that has completed, run by Sameek Roychowdhury. The registered enrollment target is 17 participants.
The verdict
NCT04233567, a Phase 2 study, has completed, sponsored by Sameek Roychowdhury.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This phase II trial studies how well infigratinib works in treating solid tumors that have spread to other places in the body (advanced or metastatic) in patients with FGFR gene mutations such as FGFR1-3 gene fusions or other FGFR genetic alterations. Mutations are any changes in the genetic material (DNA) of a cell. FGFR proteins are involved in cell division, cell maturation, formation of new blood vessels, wound healing, and bone growth, development, and maintenance. FGFR mutations can cause the FGFR protein to become over-active in diseases such as cancer. Infigratinib may stop the growth of tumor cells by blocking FGFR proteins in these tumors.
Interventions
- DRUG Infigratinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-01-16 |
| Est. Completion | 2024-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04233567
The ClinicalTrials.gov registry entry for NCT04233567 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sameek Roychowdhury, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Infigratinib is the first listed.
NCT04233567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04233567 about?
NCT04233567 is a clinical study titled "Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations". This phase II trial studies how well infigratinib works in treating solid tumors that have spread to other places in the body (advanced or metastatic) in patients with FGFR gene mutations such as FGFR1-3 gene fusions or other FGFR genetic alterations. Mutations are any changes in the genetic materia...
What is the current status of trial NCT04233567?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2020-01-16. Estimated completion is 2024-12-12.
What interventions are being tested in trial NCT04233567?
The interventions under investigation include: Infigratinib (DRUG).
Who is sponsoring clinical trial NCT04233567?
This trial is sponsored by Sameek Roychowdhury, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.